Brief: China NT Pharma Group Sees Consol Loss For FY
30/01/2019 15:20
Jan 30 (Reuters) - China NT Pharma Group Co Ltd 1011.HK :
* GROUP IS EXPECTED TO RECORD CONSOLIDATED LOSS FOR YEAR
ENDED 31
DECEMBER 2018
* EXPECTED RESULT DUE TO NET LOSS FROM CHANGE IN FAIR VALUE
OF
FINANCIAL LIABILITIES OF CONVERTIBLE PREFERENCE SHARES IN
COMPANY
Source text for Eikon: ID:nHKSc6Lqs2
Further company coverage: 1011.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China NT Pharma
See all newsBrief: China NT Pharma Receives Cietac Beijing Arbitration Award On July 20
Brief: China NT Pharma Establishes Formal Whistleblowing Policy
Brief: China NT Pharma Group Says Zhang Bozhi Resigns As CEO
Brief: China NT Pharma Group Says Expected Loss For Year Further Reduced By HK$15.4 Million As Compared With Prior Guidance
Brief: China Nt Pharma Expects Net Loss Attributable Of RMB25 MLN To RMB30 MLN In FY